Atara Biotherapeutics opened higher at $8.37, compared with its previous close of $8.23. In the last trading session, the stock traded between $7.95 and $8.41. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Atara Biotherapeutics is now worth
$ 1.79
Resulting in a loss of
$ 98.21 (98.21%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.38 (-4.64%)
Day High
$8.41
Day Low
$7.95
Day Open
$8.37
Prev Close
$8.23
Volume
13,790
1W Return
-6.40%
1M Return
-16.02%
3M Return
-12.28%
6M Return
-10.62%
1Y Return
-37.52%
Fundamentals
Market Cap ($ Mn)
80
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
630.06%
EPS (TTM)
$-0.51
Investment Returns
1 Week
-6.40%
1 Month
-16.02%
3 Months
-12.28%
6 Months
-10.62%
9 Months
70.98%
Financials
Quarterly
All values in $ Mn
32.8
Dec 24
98.1
Mar 25
17.6
Jun 25
3.5
Sep 25
1.6
Dec 25
0.6
Jun 26
Updates
11Nov
Atara Biotherapeutics files prospectus for up to $200M in securities
Atara Biotherapeutics Inc filed a base prospectus with the SEC. The filing covers the offer, issuance and sale of securities. Maximum value of the proposed offering is $200 million.
2 days ago
13Aug
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027
Atara Biotherapeutics reported Q2 2026 EPS of $(0.32) and revenue of $0.6 million, beating sales estimates by 71.82%. The company achieved an 87% year-over-year reduction in operating expenses and extended its cash runway into mid-2027. Key developments include a productive FDA Type A meeting for tabelecleucel and ongoing support for Pierre Fabre's BLA resubmission.
3mo ago
13Jun
Atara Biotherapeutics appoints Brian Cherry to its board
Atara Biotherapeutics appoints Brian Cherry to its board, succeeding Carol Gallagher. Cherry brings 25+ years of investment experience, including at Oak Hill Capital. His expertise aligns with Atara's focus on shareholder value and strategic growth.
